While many women experience significant weight loss and improved blood sugar control, its essential to consider the reported adverse events, which are generally mild to moderate but require monitoring
Additionally, some small studies have explored how medications in the GLP-1 receptor agonist class may affect metabolic and hormonal markers in people with PCOS
This paper is a case report of a patient with the MMNST, hoping to increase the clinical diagnosis rate of this disease and let patients get earlier and better a treatment [5]
Experts hope the drug will be useful for both obesity and liver disease
However, ideally in clinical practice, we hope to achieve at least 10-15% [bodyweight loss], which can lead to more meaningful metabolic health, says Glickman, a triple board certified family medicine, lifestyle medicine, and obesity medicine physician and the founder of Revolution Medicine